AI Consensus Investment Thesis
Ginkgo Bioworks (DNA) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
PARTIAL SELL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$6.38
-19.0%5-Year
PARTIAL SELL$5.78
-26.6%Latest flagship insight
Biological Platform Pivot Confronts Severe Cash Burn And Permanent Share Dilution
A high consensus emerges across independent reports that aggressive cost rationalization and autonomous laboratory deployments will ensure operational survival. However, persistent quarterly cash burn, unyielding facility lease obligations, and relentless at-the-market share dilution will permanently limit per-share equity recovery over the five-year forecast horizon.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Superintelligence (Anthropologist), Warren Buffett (Value Purist), Machiavelli (Insider), Universal Investor (Polymath), Ray Dalio (Strategist), J.P. Morgan (Titan), Elon Musk (Visionary), Michael Burry (Vulture), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Ginkgo Bioworks at the forecast anchor (2026-09-18): $7,339 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 7.31 | -7.28% | -7.28% | Third-quarter results reflect continued top-line contraction across legacy cell programs following biosecurity deconsolidation. Persistent cash burn and year-end tax-loss selling across unprofitable life science platforms generate moderate valuation compression despite initial overhead savings. |
| Q1 2027 | 6.76 | -7.50% | -14.23% | Audited full-year results confirm annual continuing revenue near eighty million dollars. Management guidance indicates ongoing cash consumption into 2027, prompting equity markets to discount shares as unabsorbed facility lease costs outpace administrative reductions. |
| Q2 2027 | 6.91 | +2.26% | -12.29% | Initial commercial revenue recognition from autonomous lab installations and standardized pharmacokinetic assay panels provides tactical support. Short covering and evidence of halved operating expenses generate a modest seasonal rebound off oversold valuation levels. |
| Q3 2027 | 6.38 | -7.68% | -19.03% | Working capital demands from customized laboratory deployments coincide with active at-the-market equity issuances. The resulting expansion in outstanding share count exerts downward mechanical pressure on per-share valuations as credit markets remain restrictive. |
| Q4 2027 | 6.00 | -5.99% | -23.88% | Unrestricted liquid reserves approach the two-hundred-million-dollar threshold, intensifying market focus on balance-sheet runway. Macroeconomic borrowing costs sustain pressure on early-stage biotechnology outsourcing, triggering institutional tax-loss rebalancing and price softening. |
| Q1 2028 | 5.90 | -1.69% | -25.17% | Execution of structured secondary equity issuance replenishes cash balances but dilutes existing shareholders. Investors digest the expanded share base, though operational disclosures show quarterly cash burn successfully compressed below thirty million dollars. |
| Q2 2028 | 5.92 | +0.37% | -24.90% | Expanding autonomous cloud laboratory utilization across academic consortia and federal agencies yields steady service receipts. Narrowed EBITDA losses and baseline contract stability encourage contrarian institutional accumulation at depressed price-to-book valuation multiples. |
| Q3 2028 | 5.60 | -5.38% | -28.94% | Delivery timing on specialized hardware deployments introduces quarterly revenue volatility. Operating lease encumbrances continue to weigh on GAAP margins, blunting earlier enthusiasm and prompting sideways consolidation across public equity trading. |
| Q4 2028 | 5.60 | +0.08% | -28.89% | Incremental partner milestone achievements from legacy collaborative pipelines inject non-dilutive gross profit. A cyclical stabilization in biotech venture funding supports forward booking visibility, prompting a moderate relief advance into year-end. |
| Q1 2029 | 5.66 | +0.98% | -28.19% | Annual reporting verifies operating losses decreased significantly as automated workcells replace manual bench research. Improved cash conversion and stabilizing liquidity reserves allow the equity to maintain a firmer fundamental valuation baseline. |
| Q2 2029 | 5.75 | +1.57% | -27.06% | Commercial adoption of standardized assay testing accelerates under domestic supply-chain security initiatives. Sequential top-line expansion across enterprise biopharma accounts validates the lab-as-a-service transition, driving measured enterprise multiple re-rating. |
| Q3 2029 | 5.62 | -2.27% | -28.72% | Competitive pricing from domestic and overseas contract research organizations limits realized assay margins. The market pauses its multiple expansion, demanding evidence that physical laboratory robotics can generate sustained economic owner earnings. |
| Q4 2029 | 5.68 | +1.10% | -27.94% | Consumables utilization and recurring software maintenance contracts across installed Nebula sites provide revenue stability. Approaching operational cash-flow parity removes residual solvency discounts, supporting modest upward drift in quoted equity pricing. |
| Q1 2030 | 5.65 | -0.56% | -28.34% | Full-year results confirm organic top-line recovery crossing one hundred twenty million dollars. While equity compensation and prior financing expand the share denominator, operational durability fosters renewed interest from fundamental healthcare turnaround investors. |
| Q2 2030 | 5.75 | +1.75% | -27.09% | High-throughput autonomous laboratory utilization surpasses seventy percent across core facilities. High incremental gross margins on routine assay runs begin absorbing fixed facility depreciation, generating tangible progress toward GAAP operating breakeven. |
| Q3 2030 | 5.67 | -1.36% | -28.07% | Modest capital expenditure requirements for robotic hardware maintenance and sensor upgrades absorb working capital. Range-bound trading prevails as investors weigh ongoing capital intensity against stabilized single-digit top-line revenue growth. |
| Q4 2030 | 5.67 | -0.03% | -28.10% | Securing multi-year federal bio-preparedness infrastructure contracts bolsters long-term cash flow predictability. Positive adjusted EBITDA prints solidify market perception of the asset as an established, specialized life science automation utility. |
| Q1 2031 | 5.70 | +0.64% | -27.63% | Audited accounts demonstrate sustainable operating self-sufficiency with minimal quarterly cash consumption. The elimination of existential balance-sheet dilution risks allows shares to consolidate firmly at revised contract-research valuation benchmarks. |
| Q2 2031 | 5.76 | +1.08% | -26.85% | Steady commercial execution in outsourced automated cell engineering generates modest free cash flow. Quoted equity prices reflect balanced institutional trading, recognizing operational survival alongside permanent historic share count dilution. |
| Q3 2031 | 5.78 | +0.34% | -26.61% | Five-year corporate reset concludes with the enterprise settled as a cash-disciplined biological automation provider. Valuation multiples reflect mature contract-service peers, fully balancing demonstrated robotic operational capabilities against a substantially expanded share base. |
The base-case economic reality reflects a capital-intensive laboratory automation provider successfully executing survival restructuring while diluting per-share owner economics. The complete deconsolidation of pandemic-era biosecurity testing has contracted continuing revenue to an annualized run rate near $80 million. Although management has aggressively halved research payroll and consolidated laboratory footprints to compress annual cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry toward $125 million to $150 million, fixed operating lease liabilities exceeding $400 million and substantial facility depreciation create severe negative operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry. Trading around 2.3 times continuing sales on enterprise valueenterprise valueA measure of total business value, commonly calculated as equity value plus debt and preferred claims, less cash and cash equivalents.View full glossary entry, the equity is highly sensitive to the velocity of at-the-market dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry, which steadily transfers asset-backed value from existing holders to incoming liquidity providers before operational breakeven arrives. The central counterargument posits that sovereign biosecurity mandates and autonomous lab validation will accelerate high-margin licensing, yet statutory safe harbors and venture capital retrenchment ensure that commercial onshoring demand materializes incrementally rather than immediately.
Key insights
- Operating lease commitments of $404 million represent inflexible senior claims that outlast headcount reductions, preventing swift GAAP profitabilitygaap profitabilityGAAP profitability refers to earnings that remain positive under generally accepted accounting principles, including standard operating and noncash expense recognition.View full glossary entry.
- Relentless at-the-market share issuance continuously dilutes net liquid asset backing, capping per-share recovery despite operational improvements.
- Commercializing autonomous laboratory hardware shifts the enterprise toward commoditized contract research, permanently precluding software-like platform valuation multiples.
The company is transforming from an overhyped science incubator into a practical, automated laboratory service provider. After its COVID-era testing business vanished, annual sales dropped sharply to around $80 million. Management has cut operating costs aggressively to save cash, but running large robotic laboratories still burns significant money each quarter. While the company holds enough cash to avoid near-term bankruptcy, it relies on selling new shares to fund operations, which continuously reduces the ownership slice of existing stockholders.
Key insights
- Heavy lease costs on large laboratory buildings remain an expensive ongoing burden despite recent staff cuts.
- Selling new shares into the market continually lowers per-share cash value and limits stock price gains.
- Shifting into contract laboratory services means earning standard industrial margins rather than high software-like profits.
Deep Dive
Prevailing market consensus views the company as a busted post-SPAC platform whose original cellular programming vision collapsed alongside biosecurity testing revenues. Media coverage and sell-side analysts anchor heavily on sixty percent top-line contraction and persistent negative cash flow, pricing the equity as a melting cash shell facing inevitable capital depletion. The outside crowd discounts the autonomous laboratory pivot as conceptual theater, assuming platform unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry are fundamentally unviable.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus views the company as a busted post-SPAC platform whose original cellular programming vision collapsed alongside biosecurity testing revenues. Media coverage and sell-side analysts anchor heavily on sixty percent top-line contraction and persistent negative cash flow, pricing the equity as a melting cash shell facing inevitable capital depletion. The outside crowd discounts the autonomous laboratory pivot as conceptual theater, assuming platform unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry are fundamentally unviable.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd correctly identifies ongoing cash consumption but overestimates the likelihood of terminal insolvency, creating an analytical mispricing. Investors treat top-line shrinkage as organic collapse rather than deliberate pruning, overlooking that aggressive restructuring has lowered operating expenses by over $300 million and secured a $302 million unencumbered liquidity runway. However, because consensus underappreciates that ongoing at-the-market share issuances will dilute future equity value to bridge operations, the stock faces persistent per-share valuation headwinds rather than an explosive operational turnaround.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst will be audited financial disclosures across the next four reporting cycles revealing whether autonomous laboratory deployments generate genuine cash collections rather than non-cash backlogbacklogThe total value of signed contracts yet to be fulfilled, representing future revenue visibility.View full glossary entry. Evidence of quarterly cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry compressing below $25 million without aggressive share issuance would validate operational stabilization. Conversely, liquid reserves breaching $200 million will trigger dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry filings, forcing the market to reprice shares strictly on diluted book valuebook valueThe net asset value of a company calculated as total assets minus total liabilities.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Stabilization
Reports agree that market positioning reflects deep pessimism following massive historic capital destructioncapital destructionA lasting loss of invested capital caused by poor returns, impairment, dilution, or uneconomic investment.View full glossary entry. The primary tension lies between seeing stabilization around a tangible liquidation floorliquidation floorA downside value estimate based on what assets could realize in a forced sale scenario.View full glossary entry versus anticipating another round of dilutive capitulation before commercial autonomous lab adoption takes hold.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry of policy rates near 4.00% and 10-year Treasury yields touching 5.0% is an acute headwind. Elevated borrowing costs depress synthetic biologysynthetic biologyEngineering biological systems or organisms to create products, materials, or industrial processes.View full glossary entry venture funding, directly curtailing client research budgets. Higher discount rates heavily penalize long-duration, non-cash-generative platform assets while making debt financing prohibitive, leaving the enterprise entirely dependent on internal cash discipline and dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry issuance.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical disagreement centers on the economic nature of the autonomous laboratory pivot and the duration of the cash runway. Optimistic perspectives argue that operating expense cuts have lowered breakeven thresholds while high-density robotics will capture surging enterprise demand for physical AI biological validation, yielding positive EBITDAearnings before interest taxes depreciation and amortizationEarnings before interest, taxes, depreciation, and amortization (EBITDA) measures operating performance before financing, tax, and certain accounting charges.View full glossary entry without catastrophic dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry. Conversely, skeptical views demonstrate that automated laboratory services represent commoditized contract research with modest pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, where fixed lease liabilities and negative operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry will exhaust liquid reserves and force severe equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry. Observing quarterly unrestricted cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry relative to autonomous lab bookings through 2027 will resolve whether the platform achieves self-funding or dilutes shareholders.
Base-Case Forces
Event Risk ScoreVery High93/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Aggressive operational expense retrenchment | Operational Efficiency | +24% | +35% | Comprehensive restructuring has reduced annual operating overhead by over $300 million since peak levels, pruning payroll and consolidating laboratory space. By compressing quarterly cash outflows toward thirty million dollars, this spending discipline preserves balance-sheet runway into late 2028, delaying emergency financing and establishing a realistic baseline for operational self-sufficiency. |
| Autonomous laboratory platform commercialization | Innovation And Product | +20% | +26% | Repositioning automated biofoundry assets into modular cloud laboratories, exemplified by deployments with national research institutes and enterprise biopharma, establishes repeatable instrumentation and service billings. Standardized robotic execution decouples service delivery from bespoke manual labor, lifting gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry on specialized assays and arresting structural top-line contraction. |
| Domestic biosecure supply-chain onshoring | Regulatory | +18% | +20% | Heightened geopolitical frictiongeopolitical frictionExternal political tensions impacting global trade and operational stability for international companies.View full glossary entry and legislative restrictions against foreign contract research organizations channel domestic biopharma discovery workflows toward audited onshore automated infrastructure. Standardized assay services directly compete on cost and regulatory provenance, securing institutional accounts and expanding the addressable commercial pipeline across the five-year horizon. |
| Federal defense biomanufacturing contracting | Political And Geopolitical | +15% | +18% | Ongoing federal prioritization of biological security and sovereign research infrastructure provides non-dilutive grant funding and multi-year defense agency subcontracts. These sovereign engagements furnish high-margin cash inflows that partially backstop commercial revenue volatility and validate specialized automation capabilities before institutional stakeholders. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Persistent balance-sheet cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry | Capital Allocation | -32% | -30% | Despite aggressive expenditure reductions, negative free cash flownegative free cash flowA condition where cash outflows for operations and investment exceed cash generated in the period.View full glossary entry running near $130 million to $150 million annually relentlessly erodes liquid reserves. Operating outflows consume asset-backed value each quarter, limiting strategic flexibility and maintaining a strict operational countdown before additional capital injections become unavoidable. |
| Ongoing at-the-market equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry | Capital Allocation | -28% | -12% | Active reliance on at-the-market equity issuance programs systematically expands the diluted common share count to subsidize operational cash deficits. Selling shares into depressed market prices transfers per-share intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry from existing stockholders to incoming liquidity providers, creating mechanical resistance against sustained equity valuation recovery. |
| Protracted biopharma venture funding retrenchment | Sector And Industry | -24% | -32% | A higher-cost-of-capital macro regimemacro regimeA persistent combination of growth, inflation, policy, and liquidity conditions affecting asset prices.View full glossary entry continues to restrict private venture deployment across early-stage biotechnology startups, the company's historical customer core. Biopharma clients aggressively cancel exploratory external programs and extend procurement cycles, suppressing new contract additions and leaving automated laboratory capacity underutilized. |
| Inflexible fixed laboratory lease encumbrances | Operational Efficiency | -20% | -22% | Substantial long-term operating lease liabilities on specialized laboratory real estate generate tens of millions in annual carrying costs that cannot be quickly eliminated. These contractual commitments act as an inescapable operational margin drag, preventing rapid GAAP profitabilitygaap profitabilityGAAP profitability refers to earnings that remain positive under generally accepted accounting principles, including standard operating and noncash expense recognition.View full glossary entry even as direct scientific payroll is reduced. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Distressed emergency equity recapitalization wipeout | 38% | -60% | Operating cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry fails to compress below $140 million annually while commercial bookings stagnate, exhausting liquid reserves toward critical operational covenants by late 2027. Forced into deeply discounted emergency equity financing or restrictive convertible preferred issuance, common shareholders suffer catastrophic dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry exceeding fifty percent, permanently impairing intrinsic capital value. |
| Enterprise autonomous lab platform rejection | 30% | -48% | Tier-one pharmaceutical primes reject third-party autonomous cloud laboratories, choosing proprietary in-house automation suites and computational generative design algorithms. Losing enterprise adoption would strand physical biofoundry hardware, forcing massive non-cash asset impairments, severe laboratory liquidations, and irreversible top-line atrophy toward low-margin boutique contracting. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Blockbuster commercial partner royalty realization | 22% | +75% | A partnered cell therapy or industrial enzyme program clears pivotal late-stage development and commercial regulatory hurdles, triggering unexpected nine-figure cash milestones and high-margin royalty streams. This non-dilutive windfall would instantly eliminate operational cash deficits, proving downstream value capture and prompting an aggressive equity re-rating across public markets. |
| Sovereign autonomous biofoundry defense mandate | 25% | +60% | Escalating biological warfare and supply vulnerabilities prompt the Department of Defense to award an exclusive multi-year infrastructure contract exceeding $300 million. Such an award would fully underwrite laboratory operating overhead, guarantee recurring baseline revenue, and remove near-term balance-sheet dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry fears, driving substantial multiple re-expansion. |
Company Financial Analysis
Ginkgo Bioworks Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The financial trajectory depicts a severe contraction following the post-pandemic runoff and subsequent divestiture of biosecurity testing. In mid-2026, quarterly revenue from continuing operations dropped to approximately $20 million, down nearly half year-over-year. Management attributes this shrinkage to intentional customer program pruning and exiting non-core projects, but operating results demonstrate that the surviving business has not yet achieved commercial scale. Nevertheless, aggressive operational discipline is taking effect. Full-year net losses narrowed significantly from $547 million in 2024 to $313 million in 2025 as research payroll was curtailed. While trailing twelve-month free cash flow remains deeply negative at -$190 million, structural expense reductions provide a viable pathway toward cash-burn containment.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 170.2M | USD -312.8M | USD -178.7M |
| 2024 | USD 227M | USD -547M | USD -382.1M |
| 2023 | USD 251.5M | USD -892.9M | USD -336.3M |
| 2022 | USD 477.7M | USD -2.1B | USD -304.5M |
| 2021 | USD 313.8M | USD -1.8B | USD -310.3M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Reported profit margins present a stark economic divergence. Accounting gross margin remained superficially elevated above 80% in 2025, suggesting that direct lab consumable costs are manageable. Yet trailing operating margins sat deeply negative near -185%, exposing an enterprise swamped by fixed overhead. This divergence occurs because extensive automated facilities and platform engineering costs sit within research and administrative overhead rather than cost of sales. Because fixed facility depreciation remains elevated against an $80 million revenue run rate, operating leverage is severely negative. Sustainable profitability requires multi-fold commercial volume growth to absorb fixed carry costs.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -315.3M | -185.3% | -183.8% |
| 2024 | USD -559.8M | -246.5% | -240.9% |
| 2023 | USD -864.4M | -343.8% | -355.1% |
| 2022 | USD -2.2B | -462.4% | -440.6% |
| 2021 | USD -1.8B | -582.6% | -583.1% |
Balance sheet and leverage
AI Review
On the surface, the balance sheet presents an appearance of defensive stability. The company closed June 2026 with $302 million in unrestricted cash and marketable securities alongside negligible conventional bank debt. On roughly 62 million shares, liquid assets provide an asset-backed cushion near $4.86 per share. However, significant hidden commitments compromise this headline liquidity. The company carries $404 million in noncurrent operating lease liabilities alongside $87 million in restricted cash. With annual cash burn guided between $125 million and $150 million, the treasury offers roughly two years of operational runway before requiring external capital replenishment.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 439.9M | USD 422.6M | USD 272.7M net debt | 4.92x |
| 2024 | USD 467.7M | USD 561.6M | USD 93.8M net cash | 5.62x |
| 2023 | USD 239.3M | USD 944.1M | USD 704.8M net cash | 6.11x |
| 2022 | USD 442.6M | USD 1.3B | USD 873.2M net cash | 8.38x |
| 2021 | USD 23M | USD 1.6B | USD 1.5B net cash | 12.79x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has executed an abrupt shift from capital-intensive empire building to strict liquidity conservation. Capital expenditures fell sharply from 27.5% of revenue in 2024 to just 4.5% in 2025, reflecting a complete freeze on speculative physical foundry construction across Boston. The era of multi-million-dollar real estate expansion has ended. Capital allocation is now focused strictly on optimizing existing modular robotics and deploying customer-sited autonomous labs like the Nebula platform. This restraint preserves dwindling liquid balances but confirms that massive physical economies of scale failed to materialize, leaving the business dependent on harvesting previously sunk capital investments.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 7.7M | USD 243.8M |
| 2024 | USD 62.5M | USD 424.1M |
| 2023 | USD 40.8M | USD 580.6M |
| 2022 | USD 52.3M | USD 1.1B |
| 2021 | USD 56.5M | USD 1.1B |
Quarterly Forecast Scenarios
Ginkgo Bioworks Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $6.9344 | $7.3791 | $8.274 | $750.26 | |
| $5.8942 | $6.9334 | $8.7704 | $736.44 | |
| $5.5459 | $7.0511 | $9.1213 | $743.40 | |
| $4.5477 | $6.5825 | $8.8476 | $755.15 | |
| $4.2293 | $6.3096 | $9.5554 | $776.22 | |
| $4.2421 | $6.3387 | $10.22 | $787.13 | |
| $4.1346 | $6.4192 | $11.14 | $802.83 | |
| $3.7211 | $6.2426 | $12.04 | $812.05 | |
| $3.5351 | $6.2869 | $12.76 | $839.18 | |
| $3.4301 | $6.4511 | $13.65 | $850.50 | |
| $3.3498 | $6.6015 | $14.33 | $872.39 | |
| $3.0217 | $6.5585 | $14.62 | $885.51 | |
| $2.8404 | $6.6891 | $15.50 | $909.56 | |
| $2.8628 | $6.8174 | $16.74 | $916.13 | |
| $2.6916 | $7.0066 | $17.91 | $936.51 | |
| $2.557 | $7.0389 | $18.80 | $947.34 | |
| $2.378 | $7.1375 | $19.56 | $969.59 | |
| $2.4256 | $7.305 | $20.53 | $979.99 | |
| $2.3285 | $7.4485 | $21.36 | $999.60 | |
| $2.2587 | $7.5443 | $22.00 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The consensus across independent reports demonstrates a robust common pattern: following the divestiture of volatile pandemic biosecurity testing, core cell-engineering revenue has contracted to an annualized run rate of approximately $80 million, while aggressive restructuring has pruned operating expenses toward a targeted annual cash burn of $125 million to $150 million. Divergence centers on whether automated laboratory infrastructure and legislative onshoring can establish self-funded commercial viability before liquid reserves deplete, or whether ongoing equity dilution will permanently erode per-share equity value. Highly weighted opinions rely on authoritative primary filings, highlighting $302 million in unrestricted liquidity alongside $404 million in noncurrent operating lease liabilities and active at-the-market equity issuance. Downweighted reports either postulate near-term liquidation while ignoring multi-year cash buffers or project rapid multi-fold multiple expansion that overlooks statutory safe harbors and biopharma venture funding contraction. The relative weights reflect proven balance-sheet facts and dilution dynamics.
Universal Investor AI
The Polymath
GPT-6 AstraExhibits superior evidence quality by reconciling post-divestiture continuing operations, quantifying $404 million in noncurrent operating lease liabilities, and modeling realistic equity issuance. The measured projection of operational survival alongside diluted per-share value is thoroughly grounded.
Universal Investor AI
The Polymath
Opus 5Offers exceptional primary-source grounding, detailing 105 active Nebula racks, Google Cloud contract restructuring, and $14 million quarterly lease drag. Its thesis of a melting valuation floor diluted by ongoing share issuance is mathematically compelling.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashDemonstrates sound economic reasoning by contrasting headline liquidity against fixed facility lease claims. It realistically projects intermediate dilution before modular lab automation reaches modest contract-service breakeven, avoiding both ungrounded optimism and liquidation assumptions.
Michael Burry AI
The Vulture
Gemini 3.8 FlashDelivers valuable forensic scrutiny of $87 million in restricted cash and encumbered Boston real estate commitments. It accurately ties cash burn to at-the-market dilution, presenting a plausible trajectory toward commoditized contract research valuation.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProvides a balanced evaluation of operational cost compression versus persistent customer venture funding headwinds. Its projection of stabilization as a specialized automation contractor reflects credible causal alignment with recent overhead cuts and lease rationalization.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProvides rigorous analysis of structural operating deficits, severe customer churn, and continuing-operations revenue compression. It accurately models ongoing cash burn and the inevitable erosion of per-share book value under sustained high capital costs.
Elon Musk AI
The Visionary
Gemini 3.8 FlashAccurately highlights the ongoing thermodynamic reality of laboratory automation versus digital software margins. It correctly identifies persistent at-the-market equity supply pressure, although its five-year terminal path slightly overstates the speed of physical asset obsolescence.
Universal Investor AI
The Polymath
Gemini 3.8 FlashEffectively details the commercial progress of the ADME-One assay platform and academic cloud lab contracts. Its five-year appreciation path is somewhat generous given ongoing at-the-market issuance, but its operational analysis is well supported.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProperly identifies that high gross margin reflects accounting classifications rather than true platform pricing power. However, it overstates the velocity of solvency collapse by ignoring the multi-year breathing window provided by remaining liquid reserves.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashPresents rigorous forensic accounting on vanishing downstream royalties and the limits of R&D pruning. However, its terminal forecast overly discounts the asset-backed cash cushion and recurring academic installations.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashOffers an insightful perspective on physical automated laboratories serving as verification bottlenecks for AI models. However, its optimistic terminal valuation underestimates the drag of substantial facility lease liabilities and dilutive equity issuance.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents a sharply articulated critique of negative operating leverage and biological trial-and-error limitations. However, it excessively penalizes terminal value by assuming near-total customer abandonment and immediate liquidation, underestimating balance-sheet runway resilience.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashConstructs an interesting upside scenario around AI biological training data demand and rapid EBITDA breakeven. However, it downplays the reality of ongoing at-the-market dilution and assumes implausibly rapid multiple expansion amid tight macro conditions.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashIdentifies legitimate regulatory tailwinds from domestic biosecurity legislation and federal defense grants. Nevertheless, it overweights these factors into an aggressive near-term re-rating, neglecting the five-year safe-harbor grace periods that defer commercial onshoring.
Research Provenance
References & Context
This Ginkgo Bioworks consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 64 deduplicated sources retained for this batch.
- 01AMP2 Receives R&D 100 Award for Advancing Anaerobic Microbial Research | Environmental Molecular Sciences Laboratoryemsl.pnnl.gov
- 02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 03NSF announces $400M investment in new national network of AI-programmable cloud laboratories in alignment with the U.S. government's Genesis Mission | NSF - U.S. National Science Foundationnsf.gov
- 04dna-20260630sec.gov
- 05Ginkgo Bioworks Holdings, Inc. - Form 10-Q - FY2026sec.gov
- 06Ginkgo Bioworks Holdings, Inc. - Form 8-K - FY2026sec.gov
- 07www.sec.govsec.gov
- 08www.sec.govsec.gov
- 09www.sec.govsec.gov
- 10Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Labbarchart.com
- 11DNA Stock Quote Price and Forecast | CNNcnn.com
- 12Ginkgo Bioworks Holdings Inc. (via Public) / Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discoveryebs.publicnow.com
- 13Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summaryfinance.yahoo.com
- 14Ginkgo Bioworks Q2 Earnings Call Highlightsfinance.yahoo.com
- 15Ginkgo Bioworks (DNA) Q1 2026 earnings reviewfinsee.ai
And 49 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
11 fieldscash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2019-12-31–2025-12-31, 7 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.